CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+6.21%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$907M
AUM Growth
+$198M
(+28%)
Cap. Flow
+$180M
Cap. Flow
% of AUM
19.88%
Top 10 Holdings %
Top 10 Hldgs %
37.32%
Holding
435
New
22
Increased
336
Reduced
40
Closed
7
Top Buys
| 1 |
Apple
AAPL
|
$25.8M |
| 2 |
Microsoft
MSFT
|
$10.9M |
| 3 |
Amgen
AMGN
|
$7.28M |
| 4 |
NVIDIA
NVDA
|
$6.87M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
$6.77M |
Top Sells
| 1 |
Micron Technology
MU
|
$6.44M |
| 2 |
ServiceNow
NOW
|
$5.1M |
| 3 |
Salesforce
CRM
|
$5M |
| 4 |
CrowdStrike
CRWD
|
$4.33M |
| 5 |
Qualcomm
QCOM
|
$3.38M |
Sector Composition
| 1 | Technology | 37.6% |
| 2 | Healthcare | 28.11% |
| 3 | Consumer Discretionary | 12.57% |
| 4 | Communication Services | 9.53% |
| 5 | Consumer Staples | 3.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
ARS Pharmaceuticals
SPRY
$1.06B
| $270K | 0.03% |
18,645
+7,262
| +64% | +$105K |
|
277
Day One Biopharmaceuticals
DAWN
$759M
| $267K | 0.03% |
19,203
+8,935
| +87% | +$124K |
|
278
Ocular Therapeutix
OCUL
$2.21B
| $261K | 0.03% |
29,989
+11,793
| +65% | +$103K |
|
279
Warner Bros
WBD
$29.1B
| $257K | 0.03% |
31,100
+16,368
| +111% | +$135K |
|
280
MongoDB
MDB
$26.2B
| $253K | 0.03% |
937
+496
| +112% | +$134K |
|
|
AVDL
281
Avadel Pharmaceuticals
AVDL
$1.46B
| $243K | 0.03% |
18,516
+7,224
| +64% | +$94.7K |
|
282
ANI Pharmaceuticals
ANIP
$2.08B
| $241K | 0.03% |
4,045
+1,582
| +64% | +$94.4K |
|
283
Tarsus Pharmaceuticals
TARS
$2.42B
| $241K | 0.03% |
7,317
+2,879
| +65% | +$94.7K |
|
284
Collegium Pharmaceutical
COLL
$1.24B
| $239K | 0.03% |
6,196
+2,352
| +61% | +$90.9K |
|
285
Xencor
XNCR
$597M
| $239K | 0.03% |
11,893
+4,650
| +64% | +$93.5K |
|
286
Phathom Pharmaceuticals
PHAT
$851M
| $237K | 0.03% |
13,134
+6,257
| +91% | +$113K |
|
287
Innoviva
INVA
$1.32B
| $232K | 0.03% |
12,033
+4,698
| +64% | +$90.7K |
|
288
Enliven Therapeutics
ELVN
$1.19B
| $232K | 0.03% |
9,085
+3,559
| +64% | +$90.9K |
|
289
Immunocore
IMCR
$1.78B
| $231K | 0.03% |
7,433
+3,053
| +70% | +$95K |
|
290
Zai Lab
ZLAB
$3.34B
| $231K | 0.03% |
9,559
+3,514
| +58% | +$84.8K |
|
291
Cogent Biosciences
COGT
$1.81B
| $227K | 0.03% |
21,051
+9,819
| +87% | +$106K |
|
292
Arm
ARM
$144B
| $227K | 0.03% |
1,587
+876
| +123% | +$125K |
|
293
Maravai LifeSciences
MRVI
$341M
| $226K | 0.02% |
27,225
+11,621
| +74% | +$96.6K |
|
|
CNTA
294
Centessa Pharmaceuticals
CNTA
$2.12B
| $217K | 0.02% |
13,593
+6,785
| +100% | +$108K |
|
295
Arcutis Biotherapeutics
ARQT
$1.94B
| $209K | 0.02% |
22,482
+8,881
| +65% | +$82.6K |
|
296
Grifois
GRFS
$6.74B
| $208K | 0.02% |
23,464
+9,130
| +64% | +$81.1K |
|
297
Travere Therapeutics
TVTX
$1.89B
| $206K | 0.02% |
14,712
+5,767
| +64% | +$80.7K |
|
298
Viking Holdings
VIK
$28B
| $204K | 0.02% |
+5,844
| New | +$204K |
|
299
Aurinia Pharmaceuticals
AUPH
$1.65B
| $202K | 0.02% |
27,502
+10,700
| +64% | +$78.4K |
|
300
Vir Biotechnology
VIR
$714M
| $197K | 0.02% |
26,280
+10,294
| +64% | +$77.1K |
|